Ovarian Cancer: It s Personal
|
|
- Victor Piers Farmer
- 5 years ago
- Views:
Transcription
1 Ovarian Cancer: It s Personal
2 Review ovarian cancer: Incidence, origin, and management Discuss genetic testing: Who, why and what? Review current treatments for ovarian cancer Enhance understanding of Individualized/Personalized Medicine for ovarian cancer
3 Ovarian cancer: Incidence, origin, and management
4 2017 Ovarian Cancer 22, th Estimated new cases 1 Most common cancer in females 2 Accessed April 30, 2017
5 1. In 2013, ~196,000 women living with ovarian cancer in the US 3 2. Incidence rates ovarian cancer slowly falling over 20 years AccessedApril 30, Gynecologic Cancers: Ovarian Cancer. Accessed August 1, SEER Stat Fact Sheets: Ovarian Cancer. Accessed August 1, 2016.
6 1. Accessed November 18, 2016 and April 30, 2017
7 Random Errors Stem Cell Divisions Types of Errors Tumor Type
8 Accessed November 24,
9 Percent of Deaths Percent of New Cases by Age Group: Ovarian Cancer 30.0% 25.0% 20.0% 18.6% 24.2% 21.3% 15.0% 10.0% 5.0% 0.0% 8.0% 6.9% 5.9% 3.8% 1.3% < >84 Age Median Age 63 at Diagnosis = SEER Stat Fact Sheets: Ovarian Cancer. Accessed August 1, 2016.
10 Its not all the same Clear Cell Low-grade serous Other Endometrioid Mucinous High-grade serous 90% of ovarian cancers are malignant epithelial tumors Prat and FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet. 2014;124(1):1-5.
11 Ovarian Surface Epithelium High-Grade Serous Carcinoma Fallopian Tube Uterus Ovarian Surface Epithelium Low-Grade Serous Carcinoma Ovary Cervix Vagina Fallopian Tube Epithelium Fallopian Tube Epithelium Clear Cell Carcinoma Endometrium Endometrium Retrograde Menstruation? Endometriosis Endometrioid Carcinoma Mucinous Carcinoma Unknown Committee on the State of the Science in Ovarian Cancer Research; Board on Health Care Services; Institute of Medicine; National Academies of Sciences, Engineering, and Medicine Washington (DC): National Academies Press (US); 2016 Apr.
12 Stage III Epithelial Ovarian Cancer: Prognosis by Cell Type Progression-Free Survival Overall Survival
13 Cancer Type Low Grade Serous High Grade Serous Molecular alterations KRAS mutations TP53 mutations NRAS mutations BRAF mutations HER2 amplification BRCA1/2 mutations Chromosomal instability Cobb, L. et al. Gynecol Oncol Res Pract. 2015; 2: 1.
14 Genetic testing: Who, why and what?
15 Non-HRD HRD Approximately 20-25% of ovarian cancer patient have a deleterious germline or somatic mutation in the BRCA1 or BRCA2 gene BRCA 1 and 2 mutations 16-18% germline 6-7% somatic TCGA, Molecular profiling of serous ovarian cancer 2011 Pennington et al. Clin Cancer Res. 2014;20(3):
16 Other indicates the genes BRIP1, PALB2, RAD51C, RAD51D, and BARD1; MMR indicates mismatch repair genes PM52, MSH6 and MLH1 Norquist, et al. JAMA Oncol Apr; 2(4);
17 Who Should Have Genetic Testing? Leading oncology societies and guidelines recommend testing all women with ovarian cancer NCCN 1 Genetic counseling and testing should be considered in women with a history of ovarian carcinoma, fallopian tube or primary peritoneal cancer SGO 2 Women diagnosed with epithelial ovarian, tubal, and peritoneal cancers should receive genetic counseling and be offered genetic testing, even in the absence of family history ASCO 3 Genetic counseling and testing should be considered in women with epithelial ovarian, fallopian tube or primary peritoneal cancer even in the absence of family history NCCN, National Comprehensive Cancer Network; SGO, The Society of Gynecologic Oncology; ASCO; American Society of Clinical Onc ology. 1. NCCN Guidelines for Breast and/or Ovarian Genetic Assessment V Accessed April 30, Lancaster et al. Gynecol Oncol. 2015;136(1): Lu et al. J Clin Oncol. 2014;32(8):
18 Clinical Value: WHY Should Genetic Testing Be Performed? Germline BRCA or other high risk mutation identified No germline mutation 1. SGO Clinical Practice Statement: Genetic Testing for Ovarian Cancer. Available at: Accessed August 1, Lancaster et al. Gynecol Oncol. 2015;136(1):3-7.
19 What to test? Mutations Can Be Germline or Somatic Germline Mutations Inherited and present in every cell in the body 1 Somatic Mutations Acquired and found only within tumor cells 2 BRCA mutated cells BRCA intact cells 1. Petrucelli et al. BRCA2 Hereditary Breast and Ovarian Cancer. In: Pagon RA, Adam MP, Ardinger HH, et al., editors. Seattle (WA): University of Washington, Seattle; [cited 01 Aug 2016]. [about p 56]. Accessed from: 2. Moschetta et al. Ann Oncol. 2016;27(8):
20 How to Test? Clinical Utility of Multigene Panel Testing Use next-generation sequencing (NGS) Detect gene mutations other beyond BRCA1/2 Assess multiple genes simultaneously rather than in sequence saves time and enhances efficiency Results may be more complex Variants of uncertain significance Genes of uncertain significance Increased probability of detecting mutations of uncertain significance Increased anxiety and/or confusion Potential for misinterpretation of results ie. Inappropriate surgery or screening 1. SGO Clinical Practice Statement: Genetic Testing for Ovarian Cancer. Available at: Accessed August 1, Lancaster et al. Gynecol Oncol. 2015;136(1):3-7.
21 Why Does BRCA status Matter? Prognostic Bolton JAMA 2012
22 Proportion of patients progressionfree Why Does BRCA status Matter? PFS by BRCAm status Number at risk Olaparib BRCAm Placebo BRCAm Olaparib BRCAm Placebo BRCAm Time from randomization (months) BRCAm (n=136) Olaparib Placebo Events: total pts (%) 26:74 (35.1) 46:62 (74.2) Median PFS, months % reduction in risk of disease progression or death with olaparib Predictive HR= % CI (0.11, 0.31); P< Ledermann, J. ESMO/ECC 2013
23 Ledermann J, et al. Lancet Oncol. 2014;15: Khanna KK. Nat Genet. 2001;27: Sanchez-Perez I. Clin Transl Oncol.2006;8: Kennedy RD. J Clin Oncol. 2006;24: TARGETING BRCA1/2 MUTATIONS PARP & Base Excision Repair Therapeutic DNA damage NAD+ PARP PARP recruitment poly(adp-ribose) PARP PARP activation and assembly of repair factors PARG PARP PAR degradation via PARG XRCC1 LigIII pol β PNK 1 LigIII XRCC1 PNK 1 End processing, gap filling, and ligation
24 Chemical structure of PARP inhibitors Rucaparib Veliparib Olaparib Niraparib Jones et al, J of Medicinal Chemistry 2015
25 PARP Inhibitors Overview PARP Status Company Comments Olaparib Rucaparib Approved: > 3 L- FDA Study-42 Study-19 EMA Approved ARIEL-2 AZ SOLO trials (1, 2, 3) Capsules to tablets Cedarinib Ph III Plat-S & R PAOLO- with Bev Clovis FM-1 Comp Dx Breakthrough FDA 4/15 ARIEL 3-Plat-S maint ARIEL 4- Recurrent Veliparib Phase III- GOG AbbVie 1 st L Maint HG serous-3 arms Niraparib Approved NOVA Tesaro Talazoparib Phase III BioMarin Medivation Myriad HRD- genomic scarring (42 = cut-off) QUADRA-Recurrent PRIMA- 1 st L maint Only in Br Ca currently
26 PARP inhibitors: Indications and Efficacy Olaparib Rucaparib Niraparib Current FDA approval Trial Name Study Design, Population Monotherapy for gbrca+ with 3+ prior therapies Study 42 Label SOLO-2 - Efficacy Phase III Maint olaparib vs placebo, PSOC > 2 priors, response, BRCA+(germline) Monotherapy for somatic or gbrca+ after 2 prior chemotherapies ARIEL2 Phase II Open-label rucaparib, 1+ prior; PSOC, PROC; measurable; BRCA + (g58.2%; s 17.2%, unk 24.6%) RR PSOC: 70% PROC: 25% Maintenance for recurrent PSOC after chemotherapy NOVA Phase III Maint niraparib vs placebo, PSOC > 2 priors, response, BRCA+(g 36.7%; s 8.5%) or BRCA WT PFS 19.1 vs 5.5m; HR=0.3 PSOC: 12.7m PROC: 7.3m gbrca+: 21 vs 5.5 m; HR=0.27 Non-gBRCA: 9.3 vs 3.9m; HR=0.45
27 PARP inhibitors: Indications and Toxicity Olaparib Rucaparib Niraparib Current FDA approval Monotherapy for gbrca+ with 3+ prior therapies Monotherapy for somatic or gbrca+ after 2 prior chemotherapies Maintenance for recurrent PSOC after chemotherapy Trial Name Study 42 Label SOLO-2 - Toxicity Phase III ARIEL2 Phase II NOVA Phase III Grade 3-4 Toxicity 19.5% anemia 10% neutropenia 2.6% nausea 4.1% fatigue 29% anemia 10% increase LFTs 7% thrombocytopenia 33.8% thrombocytopenia 25% anemia 19.6% neutropenia 8.2% fatigue 8.2% hypertension All Grades Toxicity 75.9% nausea 65.6% fatigue 78% nausea 78% fatigue
28 Kaufman B, et al. JC Single Agent, Many Tumor Types
29 Mirza, MR N Engl J Med. 2016
30 NOVA Trial: PFS Results stratified by BRCA and HRD Status Niraparib n=138 gbrcam n=203 Placebo n=65 Non-gBRCAm, HRD+ N=162 Niraparib n=106 Placebo n=56 Overall nongbrcam N=350 Niraparib n=234 Placebo n=116 PFS Median, Months (95% CI) 21.0 (12.9, NR) 5.5 ( ) 12.9 ( ) 3.8 ( ) 9.3 ( ) 3.9 ( ) Hazard Ratio, p value HR, 0.27 P < HR, 0.38 P < HR, 0.45 P < Mirza, MR N Engl J Med. 2016
31 Swisher, EM Lancet Oncology. 2017
32 ARIEL 2 ARIEL 2: Presented by R. Kristeleit at 2015 ECCO Meeting
33 Current treatments for ovarian cancer
34 FDA-approved Drugs for Ovarian Cancer For 1st-line therapies both RR and OS have been the basis of drug approvals For 2nd- and 3rd-line therapy, RR, PFS, and OS have been the basis of approvals Gemcitabine Carboplatin PlSOC (2006) Olaparib > 3L BRCAm (2014); Carboplatin Paclitaxel PLD-Acc Rucaparib- Acc (1989) (1992, 1998) ROC ROC (2016) (1999)* Cisplatin (1978) Altretamine (1990) Objective response (RR) Clinical benefit (RR, no PFS, no OS) Clinical benefit (no PFS, no OS*, OS^) Clinical benefit (RR, PFS, no OS) Clinical benefit (RR, PFS, OS) Clinical benefit (PFS, no OS) Topotecan ROC (1996) PLD- Full ROC (2005) ^ (2006) Chemo + Bevacizumab (2014) PlROC Chemo + Bevacizumab PlSOC (2016) Niraparib- PsROC Maint (2017)
35 EOC, epithelial ovarian cancer; IV, intravenous; IP, intraperitoneal. Image curtesy of Dr. Robert Coleman 1. Ledermann et al. Ann Oncol. 2013;24 Suppl 6:vi du Bois. Cancer. 2009;115(6): cytoreduction of all macroscopic visible disease 1
36 Emerging new multiplex classification system Histology Molecular signature Treatmentfree interval Number of prior chemotherapy regimens 1. HGSC/ endometrioid 2. Other, specify 1. BRCA mutation 2. BRCA-like 3. Other, specify 1. <3 months months 3. >12 months 1. 3 or fewer 2. >3 Alvarez et al. Gynecol Oncol. 2016;141(3):405-9.
37 Individualized/Personalized Medicine for Ovarian Cancer
38 Individualized Cancer Therapy
39 Confluence of Multiple Advances Pharmacogenomics Bioinformatics Personalized Medicine Translational Genomics Molecular bio Pharmacometabonomics Companion Diagnostics
40 Improved Efficacy Overcoming drug resistance Enhanced tumor delivery Tumor specificity Intellectual Appeal Rational Targets New era Numerous molecular aberrancies Altered Toxicities < Myelosuppression < Alopecia < Neuropathy > Hemorrhage > DVT Challenges Assessing Activity Defining relevant targets Costs
41 Underlying Molecular Biology of High- Grade Serous Ovarian Cancer TCGA Ovarian - TCGA GBM - TCGA Lung - TSP
42 Non-HRD HRD Approximately 20-25% of ovarian cancer patient have a deleterious germline or somatic mutation in the BRCA1 or BRCA2 gene BRCA 1 and 2 mutations 16-18% germline 6-7% somatic TCGA, Molecular profiling of serous ovarian cancer 2011 Pennington et al. Clin Cancer Res. 2014;20(3):
43 NOVA Trial: PFS Results HRD Positive Stratified by BRCA Status HRD Positive BRCAwt N=115 HR=0.38 ( ) P<0.001 HRD Positive sbrcam N=47 HR=0.27 ( ) P=0.02 Non gbrcam - HRD Negative N=134 HR=0.58 ( ) P=0.02
44 Summary Rucaparib: Overall Response Rate and Duration of Response for Study 10 and ARIEL2 Study 10 ARIEL2 RECIST ORR% RECIST + CA125 PFI 6-12 months Median PFS (mo) (90% CI) gbrcam BRCAm (g + s) BRCA-like Biomarker Negative 65% 1 75% 3 30% 2 13% 2 81% 1 82% 2 45% 2 21% 2 88% (9.0, NR) (5.2, 7.6) (3.5, 7.1) Presented By 1. R. Shapira-Frommer R, 2015 ASCO Annual Meeting. Abstract Iain McNeish at 2015 ASCO Annual Meeting. 3. R. Kristeleit at 2015 ECCO Meeting.
45 Clinical Trials Biologic Therapies for Rare Epithelial Ovarian Cancers Herzog et al. FDA Workshop; 2015
46
47 18 studies with 977 cases Frequency of the MSI-H phenotype in unselected ovarian cancer ~12% Range 0-37% More common in mucinous and endometrioid subtypes Pal, T Clin Cancer Res 2008
48 Molecular Analysis for Therapy Choice: NCI MATCH 03/13/ 54
49 NCI-MATCH Objective To determine whether matching certain drugs or drug combinations in adults whose tumors have specific gene abnormalities will effectively treat their cancer, regardless of the cancer type This is a signal-finding trial treatments that show promise can advance to larger, more definitive trials 03/13/ 56
50 NCI-MATCH Overall Match Rate as of 03/13/2017 Around 20% of patients have a gene abnormalit y matching one being studied 03/13/ 57
51 Future of Ovarian Cancer Treatment
52 Blockade of PD-1/PD-L1 or CTLA-4 Signaling CTLA4 Tumor PD1/PD-L1 Ipilimumab* Tremelimumab * FDA-approved Adapted from Ribas A. N Engl J Med. 2012;366(26): Nivolumab* Pembrolizumab* Atezolizumab* Avelumab Durvalumab
53 Ovarian Immune Checkpoint Inhibitors Overview Brand Name Mfg Ipilimumab 1 Nivolumab 2 Pembrolizumab 3 Avelumab 4 Atezolizumab Yervoy BMS Opdivo BMS Keytruda Merck N/A Pfizer Tecentriq Genentech Isotype IgG1 IgG4 IgG4 IgG1 IgG1 Targets CTLA-4 PD-1 PD-1 PD-L1 PD-L1 ADCC Yes 5 No 6 No/Minimal 7 Yes 8 Yes 8 Approved indications (Date) Melanoma (2011) Melanoma (2014), Hodgkin s (2016), RCC (2015), NSCLC (2015) Melanoma (2014), NSCLC (2015) H & N (2016) Merkel cell Pend (2016) Bladder (2016) NSCL (2016) 1. Hodi FS et al. Proc Natl Acad Sci USA. 2008;105: Hamanishi J et al. J Clin Oncol. 2015;33: Varga A et al. Presented at ASCO Abstract Disis ML et al. Presented at ASCO Abstract Romano E et al. Proc Natl Acad Sci U S A. 2015;112(19): Wang C, Thidium KB, Han M, et al. Cancer Immunol Res. 2014;2(9): Homet Moreno B, Ribas A, et al. Br J Cancer. 2015;112(9): Boyerinas B et al. Cancer Immunol Res. 2015;3:
54 Ovarian Immune Checkpoint Inhibitors Ipilimumab 1 Nivolumab 2 Pembrolizumab 3 Avelumab 4 N Patient population Metastatic ovarian carcinoma Platinum-resistant, post-taxane Failure or inability to receive standard Tx; PD-L1+ Recurrent postplatinum Prior therapies NR 4: 55% 4: 80.8% 3: 65.3% (not including adjuvant) PD-L1+ prevalence NR 80% (IC 2/3) 100% ( 1% TC) 77% ( 1% TC) Median follow-up NR 11 months NR 12.4 months TRAE, any 22% 95% 69.2% 66.1% TRAE, Gr 3+ NR 40% 3.8% 6.5% ORR (95% CI) NR 15% ( ) 11.5% ( ) 9.7% ( ) DCR (95% CI) NR 45% (23-69) 34.6% (17-56) 54% (45-63) mpfs NR 3.5 months NR 2.6 months mos NR 20 months NR 10.8 months DCR, disease control rate; NR, not reached; TC, tumor cell; TRAE, treatment-related adverse event. 1. Hodi FS et al. Proc Natl Acad Sci U S A. 2008;105: Hamanishi J et al. J Clin Oncol. 2015;33: Abstract Varga A et al. Presented at ASCO Disis ML et al. Presented at ASCO Abstract 5533.
55 Neoadjuvant therapy 3-4 cycles Resistant/ refractory JAVELIN Ovarian 200 (avelumab) NRG GY-009 (atezolizumab) KEYNOTE 100 (pembrolizumab) Pembrolizumab + bevacizumab EORTC-1508 (atezolizumab) Lack of response or early recurrence (<6 mo) Debulking surgery 1 st -line platinum-based chemotherapy Response 1 st -line maintenance Late recurrence (>6 mo) = platinum sensitive Re-treat with platinum Response 2 nd -line maintenance Re-treat with platinum Response Late recurrence (>6 mo) = platinum sensitive = frontline JAVELIN Ovarian 100 (avelumab) Pembrolizumab + chemotherapy = recurrent = PS = PS recurrence ATALANTE (atezolizumab) KEYNOTE 100 (pembrolizumab) Pembrolizumab + bevacizumab PS, platinum sensitive. 1. NCCN guidelines. Version Clinicaltrials.gov. Accessed October 11,
56 Review ovarian cancer: Incidence, origin, and management Overall ovarian cancer is a rare disease Classification of ovarian cancer patients is evolving as data on molecular signatures emerge Cornerstone of management is surgery and chemotherapy Survival continues to improve Discuss genetic testing: Who, why and what? Importance of genetic testing for all women with ovarian cancer Genetic testing now has treatment implications besides clinical value in prognosis and cascade testing Review current treatments for ovarian cancer PARP inhibitors approved for several indications in ovarian cancer Enhance understanding of Individualized/Personalized Medicine for ovarian cancer Individualization based on histologic subtypes and mutation status Studies of treatment strategies targeting the hallmarks of cancer are ongoing or in development
Practical Guidance and Strategies for PARP Inhibition. Nicoletta Colombo, MD University of Milan-Bicocca European Institute of Oncology Milan, Italy
Practical Guidance and Strategies for PARP Inhibition Nicoletta Colombo, MD University of Milan-Bicocca European Institute of Oncology Milan, Italy Clinical Data Maintenance therapy : BRCA-mutated or all
More informationMedicina de precisión en cáncer de ovario: Determinación de BRCA germinal y somático
Medicina de precisión en cáncer de ovario: Determinación de BRCA germinal y somático Dra. Cristina Martin Lorente Hospital de la Santa Creu i Sant Pau. Barcelona Introduction Ovarian cancer is the fifth
More informationA New String to the Bow in the Treatment of Advanced Ovarian Cancer Bradley J. Monk, MD, FACS, FACOG
A New String to the Bow in the Treatment of Advanced Ovarian Cancer Bradley J. Monk, MD, FACS, FACOG Arizona Oncology (US Oncology Network) Professor, Gynecologic Oncology University of Arizona and Creighton
More informationPARP Inhibitors: Patients Selection. Dr. Cristina Martin Lorente Hospital de la Santa Creu i Sant Pau Formigal, June 23th 2016
PARP Inhibitors: Patients Selection Dr. Cristina Martin Lorente Hospital de la Santa Creu i Sant Pau Formigal, June 23th 2016 OVARIAN CANCER (OC): MULTIPLES DISEASES Different types with different behaviour
More informationUpdate on PARP inhibitors: opportunities and challenges in cancer therapy
Update on PARP inhibitors: opportunities and challenges in cancer therapy Vanda Salutari Unità di Ginecologia Oncologica Fondazione Policlinico Universitario A. Gemelli vanda.salutari@policlinicogemelli.it
More informationGenetic Testing For Ovarian Cancer: When, How And Who? Judith Balmaña, MD, PhD University Hospital Vall d Hebron Barcelona, Spain
Genetic Testing For Ovarian Cancer: When, How And Who? Judith Balmaña, MD, PhD University Hospital Vall d Hebron Barcelona, Spain Why Would We Consider Genetic Testing in Patients With Ovarian Cancer?
More informationInhibidores de PARP en cáncer de ovario
Inhibidores de PARP en cáncer de ovario Ma Pilar Barretina Ginesta Servicio Oncología Médica Hospital Universitari Dr. J. Trueta Institut Català d Oncologia Coordinación científica: Dr. Fernando Rivera
More informationRicombinazione omologa nel carcinoma ovarico: BRCA e oltre. F. Raspagliesi MD
Ricombinazione omologa nel carcinoma ovarico: BRCA e oltre F. Raspagliesi MD raspagliesi@istitutotumori.mi.it BRCA molecular signature in ovarian cancer In a pooled analysis of 26 observational studies
More informationDr. Josep M. Del Campo Clínica Diagonal. Barcelona
Dr. Josep M. Del Campo Clínica Diagonal. Barcelona Nuevas Oportunidades en Cáncer de Ovario Cancer de Ovario: Es una enfermedad única? Cáncer de Ovario: Tratamiento actual Tratamiento inicial: sin cambios
More informationVirtual Journal Club. Ovarian Cancer. Reference Slides. Platinum-Sensitive Recurrent Ovarian Cancer: Making the Most of Emerging Targeted Therapies
Virtual Journal Club Ovarian Cancer Reference Slides Platinum-Sensitive Recurrent Ovarian Cancer: Making the Most of Emerging Targeted Therapies Mansoor R. Mirza, MD Copenhagen University Hospital Rigshospitalet
More informationGOG-172: Survival Outcomes
CHEMOTHERAPY GOG-172: Survival Outcomes Progression-Free Survival Overall Survival Proportion Progression-Free 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0.0 Rx Group IV IP PF Failed Total 50 160 210 63 142
More informationESMO PRECEPTORSHIP IN IMMUNO-ONCOLOGY
ESMO PRECEPTORSHIP IN IMMUNO-ONCOLOGY LUGANO, MAY 4-5, 2018 Clinical development in ovarian cancer C. Sessa, CH CONTENT Rationale for immunotherapy in ovarian cancer Clinical data with single agent immune
More informationPARP inhibitors for breast cancer
PARP inhibitors for breast cancer Mark Robson, MD Memorial Sloan Kettering Cancer Center Agenda Mechanism of action Clinical studies Resistance mechanisms Future directions Poly (ADP-ribose) Polymerases
More informationImportanza del test genetico nel carcinoma mammario ed ovarico
Importanza del test genetico nel carcinoma mammario ed ovarico Lorena Incorvaia Azienda Ospedaliera Universitaria Policlinco «P.Giaccone» Palermo UOC Oncologia Medica Ovarian Cancer Breast Cancer The range
More informationGOG212: Taxane Maintenance
GOG212: Taxane Maintenance Epithelial Ovarian or Primary Peritoneal Cancer Optimal or Suboptimal Cytoreduction Clinical C with normal CA125, no symptoms, normal CT Primary Carboplatin and Paclitaxel (or
More informationCurrent Medical Oncology Approaches to Gynecologic Cancers. Mihaela Cristea, MD Associate Professor Medical Oncology
Current Medical Oncology Approaches to Gynecologic Cancers Mihaela Cristea, MD Associate Professor Medical Oncology Nothing to disclose DISCLOSURE Ovarian Cancer Objectives: a. To discuss new FDA approved
More informationOvarian Cancer: Implications for the Pharmacist
Ovarian Cancer: Implications for the Pharmacist Megan May, Pharm.D., BCOP Objectives Describe the etiology and pathophysiology of ovarian cancer Outline the efficacy and safety of treatment options for
More informationUpdates in Immunotherapy for Urothelial Carcinoma
Updates in Immunotherapy for Urothelial Carcinoma Andrew J Armstrong MD ScM FACP DUA 2018 Copyright 2006 SciMed. Talk Outline Immunotherapy progress in 2017: 5 new approved PD-1/PD-L1 inhibitory agents
More information2/21/2016. Cancer Precision Medicine: A Primer. Ovarian Cancer Statistics and Standard of Care in 2015 OUTLINE. Background
Cancer Precision Medicine: A Primer Rebecca C. Arend, MD Division of Gyn Oncology OUTLINE Background Where we are Where we have been Where we are going Targeted Therapy in Ovarian Cancer How to Individualized
More informationTREATMENT FOR RELAPSING PLATINUM SENSITIVE EPITHELIAL OVARIAN CANCER
TREATMENT FOR RELAPSING PLATINUM SENSITIVE EPITHELIAL OVARIAN CANCER Sandro Pignata, MD, PhD Sabrina Chiara Cecere, MD Uro-Gynecological Department, Division of Medical Oncology, IRCCS National Cancer
More informationOptimizing DNA Damage Response- Targeting Therapies: Focus on Genetic Testing and Counseling
Disclaimer This slide deck in its original and unaltered format is for educational purposes and is current as of May 2017. The content and views presented in this educational activity are those of the
More informationOvarian Cancer. Georgia McCann, MD. Division of Gynecologic Oncology
Ovarian Cancer Georgia McCann, MD Division of Gynecologic Oncology Myth: Ovarian cancer is a silent killer Non-specific Abdominal pain, discomfort Bloating, back pain Urinary urgency Constipation Tiredness
More informationOvarian Cancer: New insights into biology and treatment
Ovarian Cancer: New insights into biology and treatment 2018 Master Class Course Ursula A. Matulonis, MD Director, Gynecologic Oncology Brock-Wilson Family Chair Dana-Farber Cancer Institute Professor
More informationNew Developments in Ovarian Cancer
New Developments in Ovarian Cancer Daniela Matei, MD Professor Gynecology Oncology Northwestern University Feinberg School of Medicine Robert H Lurie Comprehensive Cancer Center Outline Recent and ongoing
More informationRecurrent Ovarian Cancer Phase 1b Results
Recurrent Ovarian Cancer Phase 1b Results December 5 th, 2017 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect Immunovaccine
More informationPrincipal changes in clinical trials involving patients with Ovarian Cancer
Verona, 18.01.2019 Principal changes in clinical trials involving patients with Ovarian Cancer Principal changes in clinical trials involving patients with Ovarian Cancer Agenda 1. Patients: Biomarker
More informationCurrent state of upfront treatment for newly diagnosed advanced ovarian cancer
Current state of upfront treatment for newly diagnosed advanced ovarian cancer Ursula Matulonis, M.D. Associate Professor of Medicine, HMS Program Leader, Medical Gyn Oncology Dana-Farber Cancer Institute
More informationFoROMe Lausanne 6 février Anita Wolfer MD-PhD Cheffe de clinique Département d Oncologie, CHUV
FoROMe Lausanne 6 février 2014 Anita Wolfer MD-PhD Cheffe de clinique Département d Oncologie, CHUV Epithelial Ovarian Cancer (EOC) Epidemiology Fifth most common cancer in women and forth most common
More informationACRIN Gynecologic Committee
ACRIN Gynecologic Committee Fall Meeting 2010 ACRIN Abdominal Committee Biomarkers & Endpoints in Ovarian Cancer Trials Robert L. Coleman, MD Professor and Vice Chair, Clinical Research Department of Gynecologic
More informationTreatment of Recurrent Ovarian Cancer
Treatment of Recurrent Ovarian Cancer Mihaela Cristea, MD Associate Professor Medical Oncology, City of Hope November 11, 2016 No disclosures Financial Disclosure Epithelial Ovarian Cancer Subtypes and
More informationControversies in the Management of Advanced Ovarian Cancer
안녕하세요 Controversies in the Management of Advanced Ovarian Cancer Mansoor R. Mirza Nordic Society of Gynaecological Oncology (NSGO) & Rigshospitalet Copenhagen University Hospital, Denmark Primary Debulking
More informationEvaluation of BRCA1/2 and homologous recombination defects in ovarian cancer and impact on clinical outcomes
Evaluation of BRCA1/2 and homologous recombination defects in ovarian cancer and impact on clinical outcomes Melinda S. Yates, PhD Department of Gynecologic Oncology & Reproductive Medicine University
More informationSOLO-1. Dott.ssa Elisabetta Sanna U.O.C. Ginecologia Oncologica- AOB Cagliari Direttore: Dott. Antonio Macciò
SOLO-1 maintenance therapy in patients with newly diagnosed advanced ovarian cancer following platinum-based chemotherapy Dott.ssa Elisabetta Sanna U.O.C. Ginecologia Oncologica- AOB Cagliari Direttore:
More informationPrecision Genetic Testing in Cancer Treatment and Prognosis
Precision Genetic Testing in Cancer Treatment and Prognosis Deborah Cragun, PhD, MS, CGC Genetic Counseling Graduate Program Director University of South Florida Case #1 Diana is a 47 year old cancer patient
More informationImmune Checkpoint Inhibitors for Lung Cancer William N. William Jr.
Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Diretor de Onco-Hematologia Hospital BP, A Beneficência Portuguesa Non-Small Cell Lung Cancer PD-1/PD-L1 Inhibitors in second-line therapy
More informationNews from ASCO. Niven Mehra, Medical Oncologist. Radboud UMC Institute of Cancer Research and The Royal Marsden Hospital
News from ASCO Niven Mehra, Medical Oncologist Radboud UMC Institute of Cancer Research and The Royal Marsden Hospital Disclosures Speaker fees: Merck, Bayer Advisory boards: Janssen-Cilag Research and
More informationCERVICAL/VULVAR CANCER CLINICAL TRIALS
CERVICAL/VULVAR CANCER CLINICAL TRIALS ALL-COMERS Primary Treatment Locally Advanced Recurrent Cervical GTFB (07-0935) TISSUE BANK ALL GYN TISSUE ETCTN (Phase II) (17-0458) LAO-MD017/#10010 Phase II Study
More informationThe OReO Study. Study design & Protocol Study design Key Inclusion criteria Patient population Recruitment and retention tools
The OReO Study A Phase IIIb, Randomised, Double-blind, Placebo-controlled, multi-centre Study of Olaparib Maintenance Re-treatment in Patients with Epithelial Ovarian Cancer Previously treated with a and
More informationMerck Pfizer Alliance Strategy in gynecologic oncology
Merck Pfizer Alliance Strategy in gynecologic oncology Lenka Kostková, MD., PhD. GCIG CCRN Educational symposium and Clinical Trials Workshop Bucharest, February 3 rd, 2018 RO/AVEOV/1217/0001 Avelumab
More informationPost-ASCO Immunotherapy Highlights (Part 2): Biomarkers for Immunotherapy
Post-ASCO Immunotherapy Highlights (Part 2): Biomarkers for Immunotherapy Lee S. Schwartzberg, MD, FACP Chief, Division of Hematology Oncology; Professor of Medicine, The University of Tennessee; The West
More informationTable Selected Clinical Trials of Anti-Angiogenesis Therapy in Gynecologic Malignancies
Table Selected Clinical Trials of Anti-Angiogenesis Therapy in Gynecologic Malignancies Uterus Study N Eligibility Regimen RR (No. of Responses) Median OS Grade 3/4 Toxicities Nimeiri et al[42] Total:
More informationBiomarker for Response and Resistance in Ovarian Cancer
2016 대한부인종양학회제 31 차춘계학술대회 New Trends in Translational Research Biomarker for Response and Resistance in Ovarian Cancer Shin-Wha Lee, M.D., Ph.D. Department of Obstetrics and Gynecology ASAN Medical Center
More informationExpert Review: The Role of PARP Inhibition in the Treatment of Breast Cancer. Reference Slides
Expert Review: The Role of PARP Inhibition in the Treatment of Breast Cancer Reference Slides Overview BRCA Mutations and Breast Cancer Patients with BRCA mutations have an estimated 55% to 65% cumulative
More informationImmunoterapia: carcinoma ovarico. Nicoletta Colombo University Of Milan-Bicocca European Institute of Oncology, Milan
Immunoterapia: carcinoma ovarico Nicoletta Colombo University Of Milan-Bicocca European Institute of Oncology, Milan What do we know in Ovarian Cancer as a Target for Cancer Immunotherapy? Overall Survival
More informationGynecologic Cancers are many diseases. Gynecologic Cancers in the Age of Precision Medicine Advances in Internal Medicine. Speaker Disclosure:
Gynecologic Cancer Care in the Age of Precision Medicine Gynecologic Cancers in the Age of Precision Medicine Advances in Internal Medicine Lee-may Chen, MD Department of Obstetrics, Gynecology & Reproductive
More informationThe Role of PARP Inhibitors in Ovarian Cancer: An Emerging Picture
The Role of PARP Inhibitors in Ovarian Cancer: An Emerging Picture This satellite symposium took place on 10 th September 2017 as part of the European Society for Medical Oncology (ESMO) Congress in Madrid,
More informationGynecologic Cancers are many diseases. Speaker Disclosure: Gynecologic Cancer Care in the Age of Precision Medicine. Controversies in Women s Health
Gynecologic Cancer Care in the Age of Precision Medicine Gynecologic Cancers in the Age of Precision Medicine Controversies in Women s Health Lee-may Chen, MD Department of Obstetrics, Gynecology & Reproductive
More informationDisclosure. Gynecologic Cancer Genetics. Audience response. Audience response. What was the result? 47%
Disclosure Cancer Genetics I have served as a moderator for an advisory board to Genentech Lee-may Chen, M.D. Professor Department of Obstetrics, Gynecology, & Reproductive Sciences UCSF Obstetrics and
More informationImmunotherapy for dmmr metastatic colorectal cancer. Prof.dr. Kees Punt Dept. Medical Oncology AUMC
Immunotherapy for dmmr metastatic colorectal cancer Prof.dr. Kees Punt Dept. Medical Oncology AUMC Active specific immunotherapy (ASI) in stage II-III colon cancer Vaccination with autologous tumor + BCG
More informationIndication for- and timing of cytoreductive nephrectomy Kidney- and bladder cancer: Immunotherapy
Indication for- and timing of cytoreductive nephrectomy Kidney- and bladder cancer: Immunotherapy Axel Bex, MD, PhD The Netherlands Cancer Institute Oslo, September 4, 2018 Financial and Other Disclosures
More informationInvestor Meetings October 2018
Investor Meetings October 2018 Safe Harbor Statement To the extent that statements contained in this presentation are not descriptions of historical facts regarding TESARO, they are forward-looking statements
More information33 rd Annual J.P. Morgan Healthcare Conference. January 2015
33 rd Annual J.P. Morgan Healthcare Conference January 2015 Forward-looking Statements This presentation contains forward-looking statements, which express the current beliefs and expectations of management.
More informationPROSTATE CANCER HORMONE THERAPY AND BEYOND. Przemyslaw Twardowski MD Professor of Oncology Department of Urologic Oncology John Wayne Cancer Institute
PROSTATE CANCER HORMONE THERAPY AND BEYOND Przemyslaw Twardowski MD Professor of Oncology Department of Urologic Oncology John Wayne Cancer Institute Disclosures I am a Consultant for Bayer and Sanofi-Aventis
More informationImmunotherapy for the Treatment of Head and Neck Cancers. Robert F. Taylor, MD Aurora Health Care
Immunotherapy for the Treatment of Head and Neck Cancers Robert F. Taylor, MD Aurora Health Care Disclosures No relevant financial relationships to disclose I will be discussing non-fda approved indications
More informationUpdate on PARP inhibitors
Professor of Medicine Harvard Medical School Boston MA Update on PARP inhibitors Ursula Matulonis, M.D. Chief, Division of Gynecologic Oncology Brock-Wilson Family Chair Dana-Farber Cancer Institute History
More informationOVARIAN CANCER CLINICAL TRIALS
OVARIAN CANCER CLINICAL TRIALS FRONT-LINE THERAPIES STG III, IV PHASE 3 GOG 3015/Roche YO39523 (16-2745) Carbo/Taxol/Bev/Atezolizumab ECOG 0-2 Allows for primary cytoreductive surgery or interval debulking
More informationRole of the Pathologist in Guiding Immuno-oncological Therapies. Scott Rodig MD, PhD
Role of the Pathologist in Guiding Immuno-oncological Therapies Scott Rodig MD, PhD Department of Pathology, Brigham & Women s Hospital Center for Immuno-Oncology, Dana-Farber Cancer Institute Associate
More informationTargeted Molecular Therapy Gynaecological Cancer Where are we now?
Targeted Molecular Therapy Gynaecological Cancer Where are we now? 0 T O M D E G R E V E S U B - S P E C I A LT Y F E L L O W G Y N A E C O L O G I C A L O N C O L O G Y U N I V E R S I T Y O F P R E T
More informationLa revolución de la inmunoterapia: dónde la posicionamos? Javier Puente, MD, PhD
La revolución de la inmunoterapia: dónde la posicionamos? Javier Puente, MD, PhD Hospital Universitario Clinico San Carlos Medical Oncology Department Thoracic & Urological Cancer Unit Complutense University
More informationNew targets in endometrial and ovarian cancer
New targets in endometrial and ovarian cancer SAMO Interdisciplinary Workshop on Gynecologic Tumors Luzern, January 16-17, 2016 C. Sessa IOSI Bellinzona Outline New targets in ovarian cancer - Cell cycle
More informationOptions for first-line cisplatin-eligible patients
The Past Options for first-line cisplatin-eligible patients Metastatic urothelial cancer Cisplatin-eligible Gemcitabine/ cisplatin MVAC or high-dose intensity MVAC Paclitaxel/ cisplatin/ gemcitabine Bellmunt
More informationNew Treatments for Early Ovarian Cancer. Jonathan Ledermann UCL Cancer Institute University College London
New Treatments for Early Ovarian Cancer Jonathan Ledermann UCL Cancer Institute University College London Lucerne Oct 213 Progression-free survival in first-line trials of platinum-based chemotherapy 1998
More informationDieta Brandsma, Department of Neuro-oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands
What is hot in breast cancer brain metastases? Dieta Brandsma, Department of Neuro-oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands 8th Annual Brain Metastases Research and Emerging Therapy
More informationPoly ADP-Ribose Polymerase (PARP) Inhibitors for Ovarian Cancer: Effectiveness and Value. Final Evidence Report. September 28, 2017.
Poly ADP-Ribose Polymerase (PARP) Inhibitors for Ovarian Cancer: Effectiveness and Value Final Evidence Report September 28, 2017 Prepared for Institute for Clinical and Economic Review, 2017 ICER Staff/Consultants
More informationClinical Trials. Ovarian Cancer
1.0 0.8 0.6 0.4 0.2 0.0 < 65 years old 65 years old Events Censored Total 128 56 184 73 35 108 0 12 24 36 48 60 72 84 27-10-2012 Ovarian Cancer Stuart M. Lichtman, MD Attending Physician 65+ Clinical Geriatric
More informationMedical Treatment of Advanced Lung Cancer
Medical Treatment of Advanced Lung Cancer Oncology for Scientists April 26, 2018 Edwin Yau, MD., Ph.D. Assistant Professor of Oncology Department of Medicine Department of Cancer Genetics and Genomics
More informationESMO SUMMIT AFRICA. Latest evidence and current standard of care in advanced ovarian cancer. C.Sessa. Cape Town February 2018
ESMO SUMMIT AFRICA Latest evidence and current standard of care in advanced ovarian cancer C.Sessa IOSI, Bellinzona, CH Cape Town 14-16 February 2018 CONFLICT OF INTEREST DISCLOSURE None Ovarian carcinoma
More informationOut of 129 patients with NSCLC treated with Nivolumab in a phase I trial, the OS rate at 5-y was about 16 %, clearly higher than historical rates.
6th Meeting on external quality assessment in molecular pathology, Naples, May 12-13, 2017 Overview of clinical development of checkpoint inhibitors in solid tumors Pr Jaafar BENNOUNA University of Nantes
More informationInvestor Call. May 19, Nasdaq: IMGN
Investor Call May 19, 2017 Nasdaq: IMGN Forward-Looking Statements This presentation includes forward-looking statements based on management's current expectations. These statements include, but are not
More informationPoly ADP-Ribose Polymerase (PARP) Inhibitors for Ovarian Cancer: Effectiveness & Value. Evidence Report. August 30, 2017.
Poly ADP-Ribose Polymerase (PARP) Inhibitors for Ovarian Cancer: Effectiveness & Value Evidence Report August 30, 2017 Prepared for Institute for Clinical and Economic Review, 2017 ICER Staff/Consultants
More informationDrug Niraparib Olaparib
Dear NCCN Value Pathway Committee, We are making this submission to provide information that we believe is relevant for developing NCCN Categories of Preference for the use of PARP inhibitors in recurrent
More informationPREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland
AWARD NUMBER: W81XWH-13-1-0421 TITLE: The Fanconi Anemia BRCA Pathway as a Predictor of Benefit from Bevacizumab in a Large Phase III Clinical Trial in Ovarian Cancer PRINCIPAL INVESTIGATOR: Elizabeth
More informationImmunotherapy for the Treatment of Head and Neck Cancers. Barbara Burtness, MD Yale University
Immunotherapy for the Treatment of Head and Neck Cancers Barbara Burtness, MD Yale University Disclosures AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim, Bristol-Myers Squibb, Merck & Co., Inc.,
More informationNCCN Guidelines for Ovarian Cancer V Meeting on 11/15/17
OV-1 External request: Submission from Vermillion/ASPiRA Laboratories to consider: Inclusion of the following recommendation in the workup for suspected ovarian cancer: OVA1 and/or Multivariate Index Assay
More informationClinical Data With PARP Inhibitors in Ovarian Cancer
Clinical Data With PARP Inhibitors in Ovarian Cancer Thomas J. Herzog, MD, FACOG, FACS Paul & Carolyn Flory Professor Clinical Director, University of CincinnaD Cancer InsDtute CincinnaD, OH Clinical Data
More informationMyriad Genetics mychoice HRD Update 06/30/2016
Myriad Genetics mychoice HRD Update 06/30/2016 1 Forward Looking Statements Some of the information presented here today may contain projections or other forward-looking statements regarding future events
More informationDNA Damage Response analyst science event
DNA Damage Response analyst science event Mene Pangalos, EVP, Innovative Medicines & Early Development and Business Development Klaus Edvardsen, Vice President, Oncology Clinical, Global Medicines Development
More informationHighlights STOMACH CANCER
UPDATES and NEWS from the Gastrointestinal Cancers Symposium in San Francisco Roma, 10-11 Febbraio 2017 Highlights STOMACH CANCER Lorenzo Fornaro, MD Unit of Medical Oncology 2 Azienda Ospedaliero-Universitaria
More informationImmune Therapy in Clear Cell Ovarian Cancer (ITICC) Hal Hirte Canadian Cancer Clinical Trials Group
Immune Therapy in Clear Cell Ovarian Cancer (ITICC) Hal Hirte Canadian Cancer Clinical Trials Group Results of Phase II Study of Durvalumab and Tremelimumab in recurrent clear cell ovarian cancer Trial
More informationModerator: Paula J. Anastasia RN, MN, AOCN Gyn-Onc Clinical Nurse Specialist Cedars-Sinai Medical Center Los Angeles, CA
Disclaimer This slide deck in its original and unaltered format is for educational purposes and is current as of May 2017. The content and views presented in this educational activity are those of the
More informationThe Ohio State University Approach to Advanced Ovarian Cancer Korean Society of Gynecologic Oncology
The Ohio State University Approach to Advanced Ovarian Cancer Korean Society of Gynecologic Oncology April 26, 2013 Larry J. Copeland M.D. Thank You for Your Friendship! 1982 1996 2013 The Ohio State University
More informationLynparza. Lynparza (olaparib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.52 Subject: Lynparza Page: 1 of 5 Last Review Date: March 16, 2018 Lynparza Description Lynparza (olaparib)
More informationFrom Research to Practice: What s New in Gynecologic Cancers?
From Research to Practice: What s New in Gynecologic Cancers? David Warshal, M.D. Head, Division of Gynecologic Oncology MD Anderson Cooper Cancer Institute Associate Professor of Obstetrics and Gynecology
More informationLung Cancer Immunotherapy
Lung Cancer Immunotherapy Luis E. Raez MD FACP FCCP Chief of Hematology/Oncology & Medical Director Memorial Cancer Institute/Memorial Health Care System Clinical Professor of Medicine Herbert Wertheim
More informationConversations in Oncology. November Kerry Hotel Pudong, Shanghai China
Conversations in Oncology November 12-13 Kerry Hotel Pudong, Shanghai China Immunotherapy of Lung Cancer Professor Caicun Zhou All materials are for scientific exchanges. Afatinib and nintedanib are not
More informationInhibidores de PARP Una realidad? dónde y cuando?
Inhibidores de PARP Una realidad? dónde y cuando? Alberto Ocana Hospital Universitario Albacete Centro Regional Investigaciones Biomédicas CIC-Salamanca DNA repair mechanisms DNA is continually exposed
More informationIMMUNOTHERAPY FOR GASTROINTESTINAL CANCERS
IMMUNOTHERAPY FOR GASTROINTESTINAL CANCERS Dr Elizabeth Smyth Cambridge University Hospitals NHS Foundation Trust ESMO Gastric Cancer Preceptorship Valencia 2018 DISCLOSURES Honoraria for advisory role
More informationReflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer
Reflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer Jimmy Ruiz, MD Assistant Professor Thoracic Oncology Program Wake Forest Comprehensive Cancer Center Disclosures I have no actual
More informationCombining PARP Inhibition and Immunotherapy for Ovarian Cancer Oliver Dorigo, MD, PhD
Combining PARP Inhibition and Immunotherapy for Ovarian Cancer Oliver Dorigo, MD, PhD Director and Associate Professor, Division Gynecologic Oncology Director Mary Lake Polan Gynecologic Oncology Research
More informationOVARIAN CANCER Updated Apr 2017 by: Dr. Jenny Ko (Medical Oncologist, Abbotsford Cancer Centre)
1 OVARIAN CANCER Updated Apr 2017 by: Dr. Jenny Ko (Medical Oncologist, Abbotsford Cancer Centre) Source: UpToDate 2017, ASCO/CCO/Alberta provincial guidelines, NCCN Reviewed by: Dr. Sarah Glaze (Gynecologic
More informationWinship Cancer Institute of Emory University Optimizing First Line Treatment of Advanced Ovarian Cancer
Winship Cancer Institute of Emory University Optimizing First Line Treatment of Advanced Ovarian Cancer Ira R. Horowitz, MD, SM, FACOG, FACS John D. Thompson Professor and Chairman Department of Gynecology
More informationGynecologic Oncology Unit IRCCS Istituto Tumori Milano G. Maltese. Milan - Italy
Gynecologic Oncology Unit IRCCS Istituto Tumori Milano G. Maltese Milan - Italy Mutations typically associated with ovarian carcinoma subtypes High-grade serous ovarian cancer TP53: encodes a protein that
More informationAngiogenesis in Ovarian Cancer
Angiogenesis in Ovarian Cancer Dr Shibani Nicum Consultant Medical Oncologist and Lead for Gynae- Oncology Oxford University Hospitals Content 1. Epithelial Ovarian Cancer : epidemiology 2. Angiogenesis-normal
More informationImmunotherapy for Breast Cancer. Aurelio B. Castrellon Medical Oncology Memorial Healthcare System
Immunotherapy for Breast Cancer Aurelio B. Castrellon Medical Oncology Memorial Healthcare System Conflicts Research support : Cascadian therapeutics, Puma biotechnology, Odonate therapeutics, Pfizer,
More informationICLIO National Conference
ICLIO National Conference Immuno-oncology In The Clinic Today Lee Schwartzberg, MD, FACP Executive Director, West Cancer Center Chief, Division of Hematology/Oncology University of Tennessee Health Science
More informationImmunotherapy in Colorectal cancer
Immunotherapy in Colorectal cancer Ahmed Zakari, MD Associate Professor University of Central Florida, College of Medicine Medical Director, Gastro Intestinal Cancer Program Florida Hospital Cancer Institute
More informationUpdate on Poly ADP ribose polymerase inhibition for ovarian cancer treatment
DOI 10.1186/s12967-016-1027-1 Journal of Translational Medicine REVIEW Open Access Update on Poly ADP ribose polymerase inhibition for ovarian cancer treatment Anselmo Papa 1*, Davide Caruso 1, Martina
More informationTRUST Trial on Radical Upfront Surgical Therapy
AGO OP.7 / TRUST TRUST Trial on Radical Upfront Surgical Therapy A close international cooperation ENGOT ov33 Ongoing Trials status update AGO-OVAR OP.7 / TRUST ENGOT-ov33 Trial setting: Sponsor: Pt with
More informationPREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland
AWARD NUMBER: W81XWH-13-1-0421 TITLE: The Fanconi Anemia BRCA Pathway as a Predictor of Benefit from Bevacizumab in a Large Phase III Clinical Trial in Ovarian Cancer PRINCIPAL INVESTIGATOR: Elizabeth
More informationWells Fargo Healthcare Conference September 6, 2018
Wells Fargo Healthcare Conference September 6, 2018 Safe Harbor Statement To the extent that statements contained in this presentation are not descriptions of historical facts regarding TESARO, they are
More information